Bradley Duffy

Array ( [id] => 12091335 [patent_doc_number] => 20170348428 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-07 [patent_title] => 'METHODS FOR FORMULATING ANTIBODY DRUG CONJUGATE COMPOSITIONS' [patent_app_type] => utility [patent_app_number] => 15/678505 [patent_app_country] => US [patent_app_date] => 2017-08-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 17804 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15678505 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13717827 [patent_doc_number] => 20170369868 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-28 [patent_title] => METHOD FOR ENGINEERING IMMUNOGLOBULINS [patent_app_type] => utility [patent_app_number] => 15/676737 [patent_app_country] => US [patent_app_date] => 2017-08-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26664 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15676737 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18085559 [patent_doc_number] => 11535677 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-12-27 [patent_title] => Chimeric antigen receptors targeting BCMA and methods of use thereof [patent_app_type] => utility [patent_app_number] => 16/303587 [patent_app_country] => US [patent_app_date] => 2017-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 45 [patent_no_of_words] => 71503 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 146 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16303587 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13840617 [patent_doc_number] => 20190023793 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-24 [patent_title] => ANTI-PD-L1 NANOBODY AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/068815 [patent_app_country] => US [patent_app_date] => 2017-08-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10854 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16068815 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14639115 [patent_doc_number] => 10364290 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-07-30 [patent_title] => Anti-HER3/HER4 antibodies binding to the beta-hairpin of HER3 and the beta-hairpin of HER4 [patent_app_type] => utility [patent_app_number] => 15/668396 [patent_app_country] => US [patent_app_date] => 2017-08-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 24 [patent_no_of_words] => 46019 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 89 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15668396 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12817459 [patent_doc_number] => 20180164325 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-14 [patent_title] => IMMUNOGLOBULIN GLYCOSYLATION PATTERN ANALYSIS [patent_app_type] => utility [patent_app_number] => 15/666432 [patent_app_country] => US [patent_app_date] => 2017-08-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8287 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15666432 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14774999 [patent_doc_number] => 20190262397 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-29 [patent_title] => CHIMERIC ANTIGEN RECEPTOR [patent_app_type] => utility [patent_app_number] => 16/320055 [patent_app_country] => US [patent_app_date] => 2017-07-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37716 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16320055 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12085966 [patent_doc_number] => 09839681 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2017-12-12 [patent_title] => 'Size tunable microbial mimetics for immunotherapy of cancer' [patent_app_type] => utility [patent_app_number] => 15/635069 [patent_app_country] => US [patent_app_date] => 2017-06-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 19 [patent_no_of_words] => 10939 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15635069 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12030836 [patent_doc_number] => 20170320935 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-09 [patent_title] => 'Polypeptides With Enhanced Anti-Inflammatory And Decreased Cytotoxic Properties And Relating Methods' [patent_app_type] => utility [patent_app_number] => 15/629119 [patent_app_country] => US [patent_app_date] => 2017-06-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 15791 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15629119 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13689623 [patent_doc_number] => 20170355766 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-14 [patent_title] => METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS IN IGG4-RELATED DISEASES [patent_app_type] => utility [patent_app_number] => 15/618051 [patent_app_country] => US [patent_app_date] => 2017-06-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46272 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 88 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15618051 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11971216 [patent_doc_number] => 20170275371 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-28 [patent_title] => 'Methods Of Treatment' [patent_app_type] => utility [patent_app_number] => 15/615032 [patent_app_country] => US [patent_app_date] => 2017-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 44 [patent_figures_cnt] => 44 [patent_no_of_words] => 26237 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15615032 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12979849 [patent_doc_number] => 20170342154 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-30 [patent_title] => MODIFIED ANTIBODY CONSTANT REGION [patent_app_type] => utility [patent_app_number] => 15/614842 [patent_app_country] => US [patent_app_date] => 2017-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26590 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15614842 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12979858 [patent_doc_number] => 20170342157 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-30 [patent_title] => Humanized Anti-CD70 Binding Agents and Uses Thereof [patent_app_type] => utility [patent_app_number] => 15/614571 [patent_app_country] => US [patent_app_date] => 2017-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27715 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15614571 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15816521 [patent_doc_number] => 10633426 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-04-28 [patent_title] => Chimeric antigen receptors targeting G-protein coupled receptor and uses thereof [patent_app_type] => utility [patent_app_number] => 15/613800 [patent_app_country] => US [patent_app_date] => 2017-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 28 [patent_no_of_words] => 75532 [patent_no_of_claims] => 49 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 135 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15613800 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12051231 [patent_doc_number] => 20170327576 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-16 [patent_title] => 'ANTI P2X7 RECEPTOR ANTIBODIES AND FRAGMENTS THEREOF' [patent_app_type] => utility [patent_app_number] => 15/599396 [patent_app_country] => US [patent_app_date] => 2017-05-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 47 [patent_figures_cnt] => 47 [patent_no_of_words] => 22975 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15599396 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11943286 [patent_doc_number] => 20170247438 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-31 [patent_title] => 'SHARK ANTIBODIES FOR CANCER THERAPY' [patent_app_type] => utility [patent_app_number] => 15/596973 [patent_app_country] => US [patent_app_date] => 2017-05-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 1979 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15596973 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12092573 [patent_doc_number] => 20170349667 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-07 [patent_title] => 'C-MET ANTIBODY COMBINATIONS' [patent_app_type] => utility [patent_app_number] => 15/596890 [patent_app_country] => US [patent_app_date] => 2017-05-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 33 [patent_no_of_words] => 49536 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15596890 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12979786 [patent_doc_number] => 20170342133 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-30 [patent_title] => sc(Fv)2 SITE-DIRECTED MUTANT [patent_app_type] => utility [patent_app_number] => 15/594791 [patent_app_country] => US [patent_app_date] => 2017-05-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13695 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15594791 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17604073 [patent_doc_number] => 11332544 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-05-17 [patent_title] => Glycan-based antibody-drug conjugates [patent_app_type] => utility [patent_app_number] => 15/493720 [patent_app_country] => US [patent_app_date] => 2017-04-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 51 [patent_figures_cnt] => 73 [patent_no_of_words] => 28597 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 110 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15493720 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13986435 [patent_doc_number] => 20190062375 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-28 [patent_title] => COMPOSITION FOR OVERCOMING RESISTANCE TO EGFR-TARGETING AGENT [patent_app_type] => utility [patent_app_number] => 16/081342 [patent_app_country] => US [patent_app_date] => 2017-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14655 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16081342 [rel_patent_id] =>[rel_patent_doc_number] =>)